Gain Therapeutics opened lower at $1.06, compared with its previous close of $1.11. In the last trading session, the stock traded between $1.01 and $1.14. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Gain Therapeutics is now worth
$ 14.51
Resulting in a loss of
$ 85.49 (85.49%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.03 (-2.25%)
Day High
$1.14
Day Low
$1.01
Day Open
$1.06
Prev Close
$1.11
Volume
2,84,654
1W Return
-1.81%
1M Return
-31.11%
3M Return
-47.41%
6M Return
-40.38%
1Y Return
-59.51%
Fundamentals
Market Cap ($ Mn)
48
PE Ratio
-
PB Ratio
6.79
PEG Ratio
-
ROE
-244.14%
ROCE
-213.77%
EPS (TTM)
$-0.11
Investment Returns
1 Week
-1.81%
1 Month
-31.11%
3 Months
-47.41%
6 Months
-40.38%
9 Months
-37.64%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
10Nov
Gain Therapeutics Q3 Results: EPS loss narrows to $(0.07), beats estimate
Gain Therapeutics reported a Q3 EPS of $(0.07). The result beat the analyst consensus estimate of $(0.12) by 41.67%. Per-share losses narrowed 53.33% from $(0.15) in the prior year.
2 days ago
29Sep
Gain Therapeutics names Gene Mack as interim CFO effective Oct. 1
Gain Therapeutics appoints CEO Gene Mack as interim CFO. Effective date for the role is October 1. Mack succeeds Principal Financial Officer Gianluca Fuggetta.
1mo ago
25Aug
Gain Therapeutics CEO to meet investors at H.C. Wainwright conference
Gene Mack, CEO of Gain Therapeutics, will hold investor meetings at the H.C. Wainwright conference. The 28th Annual Global Investment Conference runs from September 14-16, 2026 in New York City. An on-demand company presentation is scheduled for September 11, 2026 with a replay available for 90 days. Lead candidate rexaceract is in Phase 1b trials for Parkinson’s disease.
2mo ago
11Aug
Gain Therapeutics Q2 Results: EPS Beats Estimates, Loss Narrows
Gain Therapeutics delivered a stronger-than-expected second-quarter performance with an EPS of $(0.11), beating estimates of $(0.14) by 21.43%. The company’s losses narrowed by 42.11% year-over-year from $(0.19), highlighting improved financial execution and a positive trajectory toward reduced operational deficits.
3mo ago
16Jul
Gain Therapeutics CEO outlines Phase 2 plans for rexaceract
Gain Therapeutics expects its $16.5M cash reserves to fund operations into Q2 2027, supporting the Phase 1b extension and Phase 2 initiation. The Phase 2 study for rexaceract is planned for Q3 2026, following positive biomarker data showing an 81% reduction in GluSph levels. The company also advanced GT-04686 and promoted Joanne Taylor to CSO and Terenzio Ignoni to COO.
3mo ago
1Jul
HC Wainwright reiterates Buy rating on Gain Therapeutics
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Gain Therapeutics. The firm maintains an $8 price target for the stock.
